hcv product sale decreas
maintain sell rate tp
estim tp base forward price-to-earnings
multipl adjust ep
provid downsid potenti
expect top-lin revenu declin
respect
gilead stock price show upward trend quarter
due recent approv product pipelin
stock market momentum therefor downsid potenti
estim base follow factor declin
revenu earn lower hcv sale quarter
gilead perform declin quarter due lower
hcv sale revenu declin
non- ep declin ep
hiv product sale increas
increas due uptak descovy-bas regimen
strong contribut biktarvi
europ hiv sale slightli y/i due avail
gener sever market
sinc approv februari biktarvi deliv
sale biktarvi also becam number one
regimen switch patient quarter biktarvi
approv eu june launch
compani namegilead scienc inc tickergildstock ratingbuyunchangedindustri viewoverweightpositivepric aug week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth septemb
incom statement
pipelin mileston anticip
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
sale yescarta gilead
complet author cancer
centr cover yescarta-elig patient
unit state
gilead announc chmp adopt posit
opinion market author applic
yescarta eu approv eu
aggress nhl
hcv product sale declin y/i
declin sequenti gilead see
stabil hcv market reflect
sequenti perform quarter gilead announc
china drug administr cda approv
epclusa treatment adult genotyp hcv
gilead believ futur support strong
grow hiv busi led launch biktarvi
 increas momentum cell therapi busi
progress emerg area nash
inflamm healthi balanc sheet expect
net product sale
current price-to-earnings
due increas stock price
quarter price-to-earnings trade averag price-to-earnings
due fall ep
expect forward price-to-earnings
recommend sell rate base
perform quarter lower hcv sale
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend yield n/a pay-out dividend date sep ex-dividend date sep last split factor new per last split date jan inform gilead scienc inc septemb
incom statement
pipelin mileston anticip
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg oper oper profit interest income- incom special charges- interest incom minor incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli septemb
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item gilead scienc inc septemb
provid oper activ decreas compar
due lower product sale higher tax payment
provid invest activ increas compar cash use invest
activ due lower purchas market secur matur
use financ activ increas compar due
repay term loan borrow connect acquisit kite higher repurchas
common stock
defer incom oper gains- increas decreas increas decreas current assets- decreas increas decreas increas current decreas increas work capital- non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant equipment- net invest financ activitiesissu issuanc capit repurchas capit payment financ charg net- discontinu financ activities- net financ net floweffect exchang rate net chang begin end septemb
gilead earn revenu declin quarter due declin
total revenu decreas compar
total product revenu declin
compar product sale
unit state europ locat
decreas due lower sale hcv product off-set
increas sale hiv product
cog increas compar
increas due amort expens relat kite
acquisit gross margin declin compar
due chang product mix
 expens increas compar
non-gaap expens increas
compar increas due up-front
collabor payment relat collabor agreement sangamo
expens associ purchas fda prioriti review voucher
stock-bas compens expens associ acquisit kite
sg expens increas compar
non-gaap sg expens increas
compar expens increas due
stock-bas compens expens associ gilead acquisit
kite higher cost support growth gilead busi
acquisit kite non-gaap sg expens increas due higher cost
support growth gilead busi acquisit kite
incom expens decreas compar
decreas due unreal loss
decreas
compar
gross margin declin
compar
due chang
interest expens compar
effect tax rate compar
non-gaap tax rate compar
net incom declin compar
non-gaap net incom compar
ep declin compar
non-gaap ep declin
compar
gilead cash cash equival market secur
compar quarter gilead
gener oper cash flow includ tax-rel payment
also paid cash dividend util stock
total revenu decreas compar
product sale decreas
compar
cog increas compar
gross margin declin compar
 expens increas compar
non-gaap expens increas
compar
sg expens increas compar
non-gaap sg expens increas
compar increas due stock-bas
compens expens associ gilead acquisit kite higher
cost support growth gilead busi acquisit
net incom declin
compar
compar
ep declin
compar
hcv product consist
epclusa harvoni vosevi
sovaldi decreas
compar
interest expens compar
effect tax rate compar
net incom declin compar
ep declin compar
total product revenu declin compar
due lower sale hcv product product sale
 compar total sale
europ compar total sale
locat compar
hcv product consist epclusa harvoni vosevi sovaldi
decreas compar
declin due lower sale harvoni epclusa sovaldi across major
market result increas competit
total revenu epclusa declin compar
total revenu declin
compar sale epclusa decreas across major
market due lower averag net sell price result increas
epclusa product sale declin compar
epclusa product sale declin
compar
epclusa product sale europ declin compar
europ epclusa product sale declin
europ compar
total revenu harvoni declin compar
total revenu declin
compar decreas major market due
lower sale volum result increas competit
harvoni product sale declin compar
sale declin compar
harvoni product sale europ compar
total sale europ declin
compar
harvoni product sale locat declin
compar total product sale locat
declin compar
hiv product sale increas compar
increas due continu uptak descovi base
product includ biktarvi descovi genvoya odefsey
descovi approv fda european commiss april
product sale descovi ftc/taf -base product
compar total product sale
compar
total revenu
harvoni declin
compar
increas
compar
sale descovi ftc/taf -base product increas
compar sale descovi
ftc/taf -base product increas
compar
total revenu
genvoya increas
compar
total sale europ compar
sale europ increas compar
increas major market due higher
sale volum patient shift away truvada ftc/tdf -base
biktarvi revenu biktarvi
approv fda februari european commiss june
genvoya approv fda european commiss novemb
total revenu genvoya increas
compar total revenu genvoya increas
compar
total revenu
odefsey increas
compar
odefsey approv fda european commiss march
june total revenu odefsey increas
compar total revenu increas
compar
truvada ftc/tdf -base product atripla complera/eviplera stribild
product sale truvada ftc/tdf -base product
compar sale compar
product sale truvada ftc/tdf -base product
compar total sale
compar
truvada ftc/tdf -base product atripla complera/eviplera stribild
decreas sale truvada ftc/tdf -base product due lower
sale volum result continu uptak descovi ftc/taf
base product sale partial off-set increas usag
truvada prep higher averag net sell price
product sale
product europ
compar
product sale truvada ftc/tdf -base product europ
compar total sale europ
compar europ
decreas due lower sale volum result avail
gener version truvada atripla continu uptak descovi
product sale truvada ftc/tdf -base product locat
compar total sale
locat compar
sale decreas
compar
product includ product hbv cardiovascular oncolog
categori inclus vemlidi viread letairi ranexa zydelig
ambisom sale decreas compar
sale decreas
compar
sale viread use treatment chronic hbv decreas
due avail gener version yescarta launch
 octob gener gener
letairi ranexa expect face gener competit unit
state start respect
pipelin mileston anticip
biktarvi approv eu june expect launch
vesatolimod complet phase studi hiv cure
capsid inhibitor initi phase studi
gs- initi phase studi
descovi complet phase studi prep
biktarvi approv
eu june
launch
approv eu aggress nhl
complet enrol phase combo
follow data
complet enrol phase indol nhl
initi phase combo
complet enrol phase studi line dlbcl
yescarta approv
eu aggress nhl
initi phase adult
complet enrol phase mcl
initi phase pediatr
initi phase cll
complet enrol phase studi anti-bcma mm
decis registr studi base phase data
complet phase studi mage solid tumor
file ind tcr target solid tumor
pipelin mileston anticip
achiev endpoint phase combin studi r/r cll
nash pbc psc ah
week data stellar phase studi nash
week data stellar phase studi nash
data phase psc
nash pbc
data phase psc nash pbc
data
phase studi
erythematosu
interim data phase studi selonsertib and/or
and/or patient advanc fibrosi due nash
interim futil analysi phase studi uc
complet phase studi ankylos spondyl
complet phase studi psoriat arthriti
data finch phase studi ra
data finch phase studi ra
data finch phase studi ra
complet enrol phase select studi uc
complet enrol phase divers studi crohn diseas
data phase studi cutan lupu erythematosu
data phase studi sjogren syndrom
complet phase studi ebola survivor
tabl show pipelin product candid gilead
tabl show pipelin product candid gilead
product pipelin updat
product pipelin updat announc gilead includ
hiv liver diseas program
announc european commiss grant market
author biktarvi treatment infect
announc research collabor licens agreement hookipa
ag hookipa grant gilead exclus right hookipa
therat vaxwav arenaviru vector-bas immun technolog
hbv hiv
announc china drug administr cda approv
epclusa treatment adult genotyp hcv infect
cda also approv epclusa combin ribavirin adult hcv
decompens cirrhosi
announc fda approv truvada- combin safer sex
practic reduc risk sexual acquir at-risk
present data intern liver congress includ
announc
complet enrol ahead schedul
two on-going phase trial evalu apoptosi signal-
regul kinas inhibitor selonsertib patient stage
fibrosi due nonalcohol steatohepat nash
result proof-of-concept studi investig combin
therapi patient nash combin selonsertib either
acetyl-coa carboxylas inhibitor select non-steroid
farnesoid receptor agonist base studi
combin therapi well toler offer addit benefit
improv nash reduc liver fat content liver cell injuri
fibrosi gilead initi larger phase studi
combin selonsertib patient advanc
fibrosi due nash
result two studi util machin learn techniqu
suggest non-invasive test perform effect liver biopsi
predict clinic outcom patient advanc fibrosi due nash
announc china
approv epclusa
treatment adult
genotyp hcv
result two studi
techniqu suggest
non-invasive test
perform effect
liver biopsi predict
clinic outcom
patient advanc
fibrosi due nash
product pipelin updat
oncolog cell therapi program
announc european medicin agenc committe medicin
product human use issu posit opinion gilead market
author applic yescarta treatment adult patient
relaps refractori diffus larg cell lymphoma primari
mediastin larg cell lymphoma two line system
present data american societi clinic oncologist annual
meet includ announc
result on-going phase studi conduct nation cancer
institut show clinic respons observ investig
solid tumor cancer caus hpv
analys studi yescarta adult patient refractori
larg b-cell lymphoma show respons statu may predict rate
progression-fre surviv treatment respons consist
across prior line therapi
analysi studi evalu investig
treatment adult patient relaps refractori acut lymphoblast
leukemia show patient experienc manag safeti
encourag efficaci irrespect prior blinatumomab use
announc new world-wide facil advanc manufactur cell
therapi peopl cancer new cooper research
develop agreement nation cancer institut develop
announc random placebo-control phase equat
studi filgotinib investig select inhibitor adult
moder sever psoriat arthriti achiev primari endpoint
improv sign symptom psoriat arthriti week
assess american colleg rheumatolog improv
world-wide facil
advanc manufactur
cell therapi peopl
cancer
announc
equat studi
filgotinib achiev
primari endpoint
improv sign
symptom psoriat
arthriti week
product pipelin updat
announc random placebo-control phase equat
studi filgotinib investig select inhibitor adult
moder sever psoriat arthriti achiev primari endpoint
improv sign symptom psoriat arthriti week
assess american colleg rheumatolog improv
announc independ data monitor committe dmc
conduct plan interim futil analysi filgotinib phase
ulcer coliti studi select patient complet
induct period phase portion studi dmc
recommend studi proceed phase plan
mg mg daili dose level biologic-experienc
announc scientif collabor verili life scienc llc verili
alphabet compani use verili immunoscap platform identifi
better understand immunolog basi three common seriou
lupus-rel diseas
collabor verili
immunoscap platform
identifi better
understand
immunolog basi
three common seriou
guidanc conclus
result reflect
strong perform hiv
yescarta launch
stabil hcv
expect net product sale
non-gaap tax rate expect rang
deliv result reflect strong perform hiv
sale continu progress yescarta launch stabil hcv
product sale revenu declin due
lower sale hcv product quarter ep
non-gaap ep declin
hiv product sale increas due uptak
descovy-bas regimen strong contribut biktarvi
 hcv sale declin q/q yescarta sale
sinc launch cancer centr author
gilead cash cash equival market secur
compar ytd stock perform
compar roa roi roe
ttm basi respect
non- reconcili
non- reconcili
non- reconcili
incom statement
pipelin mileston anticip
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin decreas ttm compar due increas cog
revenu growth ttm compar
oper margin declin ttm compar due increas expens
revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth gilead scienc inc septemb
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale gilead scienc inc septemb
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn equiti gilead scienc inc septemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per share- book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out ratio- day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item gilead scienc inc septemb
balanc sheet ratio
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas business- sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc dividends- net chang capit free septemb
current price-to-earnings due increas stock price
quarter price-to-earnings trade averag price-to-earnings due fall ep avg-
expect forward price-to-earnings
incom statement
pipelin mileston anticip
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvalueblackrock vanguard group inc capit research global fmr parnassu invest price row associ northern trust top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf vanguard institut fund-institut invest compani parnassu equiti powershar exhg trade fd tr-powershar qqq tr seri ishar nasdaq biotechnolog ishar vanguard growth septemb
developmentsyescarta axicabtagen ciloleucel receiv european market author treatment relaps refractori dlbcl pmbcl line system therapyaugust agilead compani announc theeuropean commiss ec grant market author yescarta axicabtagen ciloleucel treatment adult patient relaps refractori diffus larg b-cell lymphoma dlbcl primari mediastin larg b-cell lymphoma pmbcl two line system therapi market author approv axicabtagen ciloleucel use countri theeuropean union norway icelandandliechtenstein china nation drug administr approv gilead genvoya elvitegravir cobicistat emtricitabin tenofovir alafenamid singl tablet regimen treatment infectionaugust scienc inc announc thechina nation drug administr cnda approv genvoya elvitegravir mg/cobicistat mg/emtricitabin mg/tenofovir alafenamid mg e/c/f/taf treatment infect genvoya first taf-bas singl tablet regimen treatment hiv approv inchina gilead announc new data impact truvada emtricitabin tenofovir disoproxil fumar pre-exposur prophylaxi prep number hiv diagnos unit statesjuli scienc inc announc result retrospect nationwid analysi impact truvada emtricitabin mg tenofovir disoproxil fumar mg tablet pre-exposur prophylaxi prep use across state district columbia data demonstr use once-daili oral truvada prep independ signific impact number new hiv infect diagnos inth unit statesfrom gadeta announc strateg collabor advanc gamma delta cell receptor technolog solid tumorsjuli agilead compani andgadeta privately-held compani focus discoveri develop novel cancer immunotherapi base gamma delta cell receptor tcr enter strateg collabor develop novel gamma delta tcr therapi variou cancer financi term kite provid research develop fund collabor gadeta elig receiv futur payment upon achiev certain regulatori mileston addit kite make up-front purchas equiti gadeta gadeta sharehold may acquir addit equiti gadeta upon achiev certain mileston kite exclus option acquir gadeta gilead scienc inc septemb
incom statement
pipelin mileston anticip
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
compar
roa roi roe
ttm basi respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit gilead scienc inc septemb
consensu view analyst trend stock
forecast
compar
multipl compar
valuat comparisongildindustri avg avgprice/earn yield avgfive-year growth forecast usdgrowth high day day day estim septemb
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim
current qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate gilead scienc inc septemb
incom statement
pipelin mileston anticip
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price show upward trend june current trade
averag daili volum share trade quarter gave return
period
stock price volatil year gave return year
rang stock
stock price shown downward trend past dip may
stock given neg return past due perform compani
gilead revenu declin due lower product sale hcv product still
abl recov situat gilead hiv product sale increas due
growth sale biktarvi recommend sell rate maintain tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
